Research reveals new therapeutic target for Huntington's disease

Research from Western University (London, Canada) has revealed a possible new target for treating movement disorders such as Huntington's disease (HD) and Parkinson's disease. Stephen Ferguson, PhD, a scientist at Western's Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviors in a HD mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted. The research is published online in Human Molecular Genetics.

HD is an inherited neurodegenerative disorder which causes uncontrolled movement, and eventually cognitive decline and emotional disturbances.

Working in the Ferguson lab where Ribeiro was a postdoctoral trainee, the scientists crossed two mouse models. One was a mouse which doesn't have glutamate receptors –they've been knocked out genetically, and the other is a HD which over-expresses mutant human Huntington protein. They found if they deleted mGluR5, they lost the pathology of Huntington's in the neurons, and they saw improvements in motor behavior which normally would be impaired in these mice.

This video is not supported by your browser at this time.
Stephen Ferguson, Ph.D., a scientist at Western University's Robarts Research Institute found a definite improvement in motor behaviours in a Huntington's disease mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 was deleted. Credit: Western University

"What we found was, if we block mGluR5, which is the we're interested in, the mice become hyper locomotive so they become able to move better than wild type mice suggesting glutamate receptors might be a good target for treating movement disorders such as Parkinson's disease. So that was a bit of a surprise that came out in the study, and we can show that genetically and pharmaceutically," says Ferguson who holds a Canada Research Chair in Molecular Neurobiology. "And the good thing is, there are mGluR5 antagonists now in stage three clinical trials for diseases such as Fragile X, so it is quite possible these drugs will be available for patients in the future."

add to favorites email to friend print save as pdf

Related Stories

Protecting the brain from a deadly genetic disease

Feb 23, 2010

Huntington's disease (HD) is a cruel, hereditary condition that leads to severe physical and mental deterioration, psychiatric problems and eventually, death. Currently, there are no treatments to slow down or stop it. ...

Alzheimer's missing link found

Sep 04, 2013

Yale School of Medicine researchers have discovered a protein that is the missing link in the complicated chain of events that lead to Alzheimer's disease, they report in the Sept. 4 issue of the journal Neuron. Researchers also f ...

Research targets brain region affected by Parkinson's

Nov 08, 2011

A team of researchers at The University of Western Ontario has demonstrated that elimination of one of the neurotransmitters in the part of the brain associated with Parkinson's disease may improve brain function without ...

Recommended for you

Why your favourite song takes you down memory lane

Aug 28, 2014

Music triggers different functions of the brain, which helps explain why listening to a song you like might be enjoyable but a favourite song may plunge you into nostalgia, scientists said on Thursday.

Transcranial Magnetic Stimulation of brain boosts memory

Aug 28, 2014

Stimulating a particular region in the brain via non-invasive delivery of electrical current using magnetic pulses, called Transcranial Magnetic Stimulation, improves memory, reports a new Northwestern Medicine ...

User comments